IGC Pharma, Inc. (IGC)
Market price: $0.24
1 valuation method
- P / B: $0.34 to $0.63 (midpoint $0.49)
How each method works
P / B: $0.34 to $0.63 (midpoint $0.49)
Values the stock at a peer multiple of its book (net asset) value — most meaningful for asset-heavy and financial companies whose balance sheet drives value.
- How it’s calculated
- We take book value per share (total assets minus total liabilities, from the latest balance sheet, divided by shares outstanding) and multiply it by the range of price-to-book multiples the peer group trades at.
- Why it fits this industry
- Where the balance sheet is the business — lenders, insurers, asset-heavy operators — the price the market pays for a dollar of net assets is a natural yardstick.
- Reading this bar
- The bar is the per-share value range this method implies: a conservative low, a central estimate, and an optimistic high. If the current price sits below the bar, the market is pricing the shares below what this method's inputs suggest; if it sits above, the market is pricing them higher. No single bar is a verdict — methods disagree for good reasons, so read the whole field together. Asset-light companies (brands, software) legitimately trade far above book value, so for them a P/B bar well below the price is usually structure, not signal.
P / B = (5.75/8.22/10.69)× book_value_per_share 0.06 ≈ 0.34/0.49/0.63 (per_share)
5 methods not shown
- EV / EBITDA: overlay rule suppressed the 'ebitda_based' category for this company
- EV / Revenue: revenue unavailable — cannot form EV / Revenue
- EV / Gross Profit: gross_profit unavailable — cannot form EV / Gross Profit
- P / E: overlay rule suppressed the 'earnings_based' category for this company
- DCF (FCFF): DCF input(s) unavailable (ebit, da, capex) — cannot build FCFF
Pre-profit company — earnings-based methods not meaningful.
Limited data — fewer than three valuation methods could be formed for this company; showing every method we can stand behind.